180 related articles for article (PubMed ID: 33674403)
1. Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim
Zwezerijnen GJC; Eertink JJ; Burggraaff CN; Wiegers SE; Shaban EAIN; Pieplenbosch S; Oprea-Lager DE; Lugtenburg PJ; Hoekstra OS; de Vet HCW; Zijlstra JM; Boellaard R
J Nucl Med; 2021 Nov; 62(11):1531-1536. PubMed ID: 33674403
[TBL] [Abstract][Full Text] [Related]
2. Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium.
Barrington SF; Zwezerijnen BGJC; de Vet HCW; Heymans MW; Mikhaeel NG; Burggraaff CN; Eertink JJ; Pike LC; Hoekstra OS; Zijlstra JM; Boellaard R
J Nucl Med; 2021 Mar; 62(3):332-337. PubMed ID: 32680929
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in
Driessen J; Zwezerijnen GJC; Schöder H; Drees EEE; Kersten MJ; Moskowitz AJ; Moskowitz CH; Eertink JJ; Vet HCW; Hoekstra OS; Zijlstra JM; Boellaard R
J Nucl Med; 2022 Sep; 63(9):1424-1430. PubMed ID: 34992152
[TBL] [Abstract][Full Text] [Related]
4. Combatting the effect of image reconstruction settings on lymphoma [
Ferrández MC; Eertink JJ; Golla SSV; Wiegers SE; Zwezerijnen GJC; Pieplenbosch S; Zijlstra JM; Boellaard R
EJNMMI Res; 2022 Jul; 12(1):44. PubMed ID: 35904645
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?
Eertink JJ; Pfaehler EAG; Wiegers SE; van T; Brug D; Lugtenburg PJ; Hoekstra OS; Zijlstra JM; de Vet HCW; Boellaard R
J Nucl Med; 2022 Mar; 63(3):389-395. PubMed ID: 34272315
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma.
Burggraaff CN; Rahman F; Kaßner I; Pieplenbosch S; Barrington SF; Jauw YWS; Zwezerijnen GJC; Müller S; Hoekstra OS; Zijlstra JM; De Vet HCW; Boellaard R;
Mol Imaging Biol; 2020 Aug; 22(4):1102-1110. PubMed ID: 31993925
[TBL] [Abstract][Full Text] [Related]
7. Prognostic parameters on baseline and interim [ 18 F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients.
Czibor S; Carr R; Redondo F; Auewarakul CU; Cerci JJ; Paez D; Fanti S; Györke T
Nucl Med Commun; 2023 Apr; 44(4):291-301. PubMed ID: 36705233
[TBL] [Abstract][Full Text] [Related]
8. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y
Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
10. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
11. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
Gupta N; Singh N
Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
[TBL] [Abstract][Full Text] [Related]
12. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
13. Repeatability of [
Kolinger GD; Vállez García D; Kramer GM; Frings V; Smit EF; de Langen AJ; Dierckx RAJO; Hoekstra OS; Boellaard R
EJNMMI Res; 2019 Feb; 9(1):14. PubMed ID: 30734113
[TBL] [Abstract][Full Text] [Related]
14. A convolutional neural network with self-attention for fully automated metabolic tumor volume delineation of head and neck cancer in [Formula: see text]F]FDG PET/CT.
Nikulin P; Zschaeck S; Maus J; Cegla P; Lombardo E; Furth C; Kaźmierska J; Rogasch JMM; Holzgreve A; Albert NL; Ferentinos K; Strouthos I; Hajiyianni M; Marschner SN; Belka C; Landry G; Cholewinski W; Kotzerke J; Hofheinz F; van den Hoff J
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2751-2766. PubMed ID: 37079128
[TBL] [Abstract][Full Text] [Related]
15. Functional Parameters of
Yang J; Zhu S; Pang F; Xu M; Dong Y; Hao J; Ma X
Contrast Media Mol Imaging; 2018; 2018():8659826. PubMed ID: 30363729
[TBL] [Abstract][Full Text] [Related]
16. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.
Ilyas H; Mikhaeel NG; Dunn JT; Rahman F; Møller H; Smith D; Barrington SF
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1142-1154. PubMed ID: 29460024
[TBL] [Abstract][Full Text] [Related]
17. Interobserver Agreement of Interim and End-of-Treatment
Burggraaff CN; Cornelisse AC; Hoekstra OS; Lugtenburg PJ; De Keizer B; Arens AIJ; Celik F; Huijbregts JE; De Vet HCW; Zijlstra JM;
J Nucl Med; 2018 Dec; 59(12):1831-1836. PubMed ID: 29728515
[TBL] [Abstract][Full Text] [Related]
18. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
19. Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements.
Eertink JJ; Arens AIJ; Huijbregts JE; Celik F; de Keizer B; Stroobants S; de Jong D; Wiegers SE; Zwezerijnen GJC; Burggraaff CN; Boellaard R; de Vet HCW; Hoekstra OS; Lugtenburg PJ; Chamuleau MED; Zijlstra JM;
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):943-952. PubMed ID: 34476551
[TBL] [Abstract][Full Text] [Related]
20. A new method for segmentation of FDG PET metabolic tumour volume using the peritumoural halo layer and a 10-step colour scale. A study in patients with papillary thyroid carcinoma.
Jun S; Kim H; Nam HY
Nuklearmedizin; 2015; 54(6):272-85. PubMed ID: 26429587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
